# Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

> **NCT06278870** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 312 (estimated)

## Conditions studied

- HER2-positive Metastatic Breast Cancer
- First-line Treatment

## Interventions

- **DRUG:** disitamab vedotin
- **DRUG:** Pyrotinib
- **DRUG:** trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** taxane drug

## Key facts

- **NCT ID:** NCT06278870
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-06
- **Primary completion:** 2031-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06278870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06278870, "Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06278870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*